相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温,避光
- 克隆性:
单克隆
- 抗体名:
alpha-Galactosidase A / GLA抗体
Antibody Type : Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
克隆号 : 2H7G10
抗体宿主 : Mouse IgG2b
缓冲液 : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
制备方法 : This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human alpha-Galactosidase A / GLA (rh alpha-Galactosidase A / GLA; Catalog#12078-H08H; NP_000940.1; Met 1-Leu 429). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
alpha-Galactosidase A / GLA抗体 Background
Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction.
alpha-Galactosidase A / GLA抗体相关产品如下:xy-6178R RAB20ras癌基因家族RAB20抗体
xy-6170R RALA+RALBRas样蛋白A+B抗体
xy-10145R Rad51Rad51抗体
xy-12290R RBMY1FRNA结合蛋白片段Y染色体家族蛋白2抗体
xy-12289R RBMY1A1RNA结合蛋白片段Y染色体家族蛋白1抗体
xy-6358R RNA polymerase IIIRNA聚合酶III抗体
xy-10118R phospho-Ron (Tyr1238+Tyr1239)磷酸化原癌基因c-Met相关酪氨酸激酶抗体
xy-12294R phospho-RUNX1(Ser303)磷酸化急性髓细胞白血病1蛋白抗体
xy-7121R Rad23DNA修复蛋白Rad23抗体
xy-12261R RTF1组织相容性复合物RTF1抗体
xy-1574R RRM1核糖核苷酸还原酶1抗体
xy-9232R RNF167环指蛋白167抗体
xy-2214R Resistin抵抗素抗体
xy-3560R RASGRF1Ras特异性鸟嘌呤核苷酸释放因子1
xy-3554R Rsk2核糖体S6激酶RSK2抗体
xy-3647R RACK1受体激活蛋白激酶C1抗体
xy-3863R ROR Gamma孤儿核受体抗体
xy-9163R RNF17环指蛋白17抗体
xy-1264R RSV呼吸道合胞病毒抗体
xy-4179R RAD9细胞周期检查控制蛋白质抗体
xy-5642R phospho-RAD9(Ser272)磷酸化细胞周期检查控制蛋白质抗体
xy-5655R phospho-RAD9(Ser336)磷酸化细胞周期检查控制蛋白质抗体
xy-5656R phospho-RAD9(Ser375)磷酸化细胞周期检查控制蛋白质抗体
xy-1483R RBBP6增殖潜能相关蛋白抗体
xy-1480R Rho CRhoC抗体
xy-9260R RNF170环指蛋白170抗体
xy-9261R RNF185环指蛋白185抗体
xy-10466R RHOGRHOG抗体
xy-10493R RPS27ARPS27A抗体
xy-2695R RANK核转录因子NF-κB受体抗体(核因子kB受体活化因子)
xy-10076R ROR alpha维甲酸相关孤儿受体α抗体
xy-10207R RSV Nucleoprotein呼吸道合胞病毒核蛋白抗体
xy-3553R RSK3核糖体蛋白S6激酶家族RSK3抗体
xy-13768R RCCD1RCCD1蛋白抗体
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验脾细胞与小鼠骨髓瘤细胞(P3-X63/Ag8)融合,融合的细胞既获得了亲代脾细胞分泌特异性抗体的特性,又具有骨髓瘤细胞大量繁殖的能力,成为一种既能分泌特异性抗体又能长命的杂交瘤细胞。该技术为抗体的分子生物学研究提供了全新的手段。极大地促进了免疫学,遗传学,分子生物学的快速发展。 但传统抗体目前也面临诸多问题,如: 每使用一管新抗体都需要进行滴定测试; 多种同型对照,实验设计繁琐; 需要添加Fc阻断试剂; 抗体不佳,阳性细胞群不明显; 抗体作为细胞生物学和生物化学中最重要的试剂之一,科学界每年在这类
LABELING ALPHA-ACTININ WITH IATR
with good stirring.The volume (ml)of borate buffer = mg IATR x 9 / (mg/ml)alpha-actinin. 4.Clarify IATR solution at 25,000 rpm,4℃,for 10 min in a 42.2Ti rotor. 5.Mix equal volumes of clarified dye and alpha-actinin in a test tube; remove
ALPHA FACTOR ARREST AND RELEASE
of approximately 3 x 10�5 M, while bar1 strains require much lower pheromone concentrations (10-8 M). To release cells from alpha factor arrest, spin down cells and wash twice (using a large volume, dependent on the size of the cell pellet anticipated
技术资料暂无技术资料 索取技术资料




